COVID-19 and Diabetes: Current Findings and Future Perspectives

Since the end of 2019, Coronavirus disease 2019 (COVID-19), which caused more than 6 million deaths worldwide, immediately gained attention as a major public health issue. The clinical spectrum of COVID-19 encompasses a wide range of conditions, from a minor upper respiratory tract infection to severe interstitial pneumonia with respiratory and even multi-organ failure and a high in-hospital mortality. This unpredictability encouraged the development of tailored vaccination tactics to control the viral propagation and slow the progression of the disease. During the pandemic, a vast amount of clinical and laboratory data was gathered, allowing researchers to learn more about the progression of the disease as well as the efficacy and safety of the anti-SARS-Cov-2 vaccine.

Due to the advent of what was then the brand-new coronavirus, COVID-19, we have now been dealing with a dreadful pandemic for almost two years. Globally, the effects of this epidemic continue to be severe, altering both our daily lives and patient care as normal.



Patients with diabetes, obesity, and cardiovascular diseases are those who are at increased risk of the most severe forms of COVID-19 and their associated mortality in various geographic regions (including Asia, Europe, North and South America, North and South Africa, as well as Australia). Over the past two years, we have discovered a wealth of lessons regarding COVID-19 and its consequences, paving the road for improved patient management of this novel disease.



With this Special Issue, we hope to update the scientific and medical community on the tight ties between COVID-19, diabetes, obesity, and cardiovascular illnesses. We therefore urge the submission of molecular biology articles that discuss both the state of the field's knowledge today and its future prospects.